SCHEMBL6162969

SCHEMBL6162969

CCOc1ccc(-c2cc(C(=O)N3CCC[C@H]3CO)c3ccccc3n2)c(F)c1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.53
NPC1 O15118 5/20 0.53
TP53 P04637 9/20 0.52
KDM4E B2RXH2 8/20 0.52
SMN1; SMN2 Q16637 7/20 0.52
LMNA P02545 7/20 0.52
ALDH1A1 P00352 7/20 0.51
MAPK1 P28482 3/20 0.51
HPGD P15428 6/20 0.49
HSD17B10 Q99714 5/20 0.49
USP2 O75604 2/20 0.49
CTNNB1 P35222 1/20 0.49
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
POLB P06746 1/20 0.45
HCRTR1 O43613 1/20 0.45
HCRTR2 O43614 1/20 0.45
HSP90AA1 P07900 1/20 0.44
SPHK2 Q9NRA0 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6163166 1.00 RAB9A (0.53) RAB9ANPC1TP53KDM4ESMN1; SMN2
SCHEMBL6164654 1.00 RAB9A (0.53) RAB9ANPC1TP53KDM4ESMN1; SMN2
SCHEMBL6165715 0.92 POLB (0.55) RAB9ATP53KDM4ELMNAALDH1A1
SCHEMBL6163699 0.92 POLB (0.55) RAB9ATP53KDM4ELMNAALDH1A1
SCHEMBL6163817 0.92 POLB (0.55) RAB9ATP53KDM4ELMNAALDH1A1
SCHEMBL6165032 0.90 HCRTR1 (0.47) RAB9ANPC1TP53KDM4ESMN1; SMN2
SCHEMBL6167631 0.90 HCRTR1 (0.47) RAB9ANPC1TP53KDM4ESMN1; SMN2
SCHEMBL6164137 0.90 HCRTR1 (0.47) RAB9ANPC1TP53KDM4ESMN1; SMN2
SCHEMBL7236604 0.87 POLB (0.48) RAB9ATP53KDM4ESMN1; SMN2LMNA
SCHEMBL7236610 0.87 POLB (0.48) RAB9ATP53KDM4ESMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1337523-B1 2,4-SUBSTITUTED PYRIDINE DERIVATIVES NEUROGEN CORP (US) 2005-10-19 EP claimed
US-20040048867-A1 2,4-Substituted pyridine derivatives NEUROGEN CORPORATION 2004-03-11 US claimed
EP-1337523-A2 2,4-SUBSTITUTED PYRIDINE DERIVATIVES NEUROGEN CORPORATION (US) 2003-08-27 EP claimed
US-6559163-B2 Agonists, antagonists or inverse agonists for GABAA brain receptors; useful in diagnosis and treatment of anxiety, depression NEUROGEN CORPORATION 2003-05-06 US claimed
US-20020161008-A1 2,4-Substituted pyridine derivatives NEUROGEN CORPORATION 2002-10-31 US claimed
WO-2002014269-A2 2,4-SUBSTITUTED PYRIDINE DERIVATIVES NEUROGEN CORPORATION (US) 2002-02-21 WO claimed
US-6559163-B2 Agonists, antagonists or inverse agonists for GABAA brain receptors; useful in diagnosis and treatment of anxiety, depression NEUROGEN CORPORATION 2003-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020161008-A1 2,4-Substituted pyridine derivatives GABARAP, GABRB1, GABARAPL1 RAB9A 628/4885NPC1 1885/4885TP53 4468/4885
US-20040048867-A1 2,4-Substituted pyridine derivatives GABARAP, GABRB1, GABARAPL1 RAB9A 628/4885NPC1 1885/4885TP53 4468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.